Research with fermented olives as a source of wild Lactic Acid Bacteria (LAB) strains with probiotic and biotechnological characteristics constitutes a promising field of work. The present study evaluated in vitro probiotic, antifungal, and antimycotoxigenic potential of LAB isolates from naturally fermented Brazilian table olives. Among fourteen LAB isolates, the Levilactobacillus brevis CCMA 1762, Lactiplantibacillus pentosus CCMA 1768, and Lacticaseibacillus paracasei subsp. paracasei CCMA 1770 showed potential probiotic and antifungal properties. The isolates showed resistance to pH 2.0 (survival ≥ 84.55), bile salts (survival ≥ 99.44), and gastrointestinal tract conditions (survival ≥ 57.84%); hydrophobic cell surface (≥27%); auto-aggregation (≥81.38%); coaggregation with Escherichia coli INCQS 00181 (≥33.97%) and Salmonella Enteritidis ATCC 564 (≥53.84%); adhesion to the epithelial cell line Caco-2 (≥5.04%); antimicrobial activity against the bacteria S. Enteritidis ATCC 564 (≥6 mm), Listeria monocytogenes ATCC 19117 (≥6 mm), Staphylococcus aureus ATCC 8702 (≥3 mm), and the fungi Penicillium nordicum MUM 08.16 (inhibition ≥ 64.8%). In addition, the strains showed the ability to adsorb the mycotoxins aflatoxin B1 (≥40%) and ochratoxin A (≥34%). These results indicate that LAB strains from naturally fermented Brazilian table olives are potentially probiotic and antifungal candidates that can be used for food biopreservation.
29 January 2026 in Journal of the American Nutrition Association
Recent evidence suggests that gut microbial imbalance may contribute to the pathogenesis of obesity-related metabolic disorders, including cardiovascular diseases. Although the underlying mechanisms remain incompletely understood, numerous studies have investigated the modulation of gut microbiota through probiotic supplementation as a potential preventive or therapeutic approach. This randomized, prospective, triple-blind, placebo-controlled clinical trial aimed to evaluate the effects of Lactococcus lactis, a probiotic with anti-inflammatory properties, on cardiometabolic risk factors associated with obesity. Fifty-two adults with elevated waist circumference and at least one additional metabolic alteration, such as elevated blood pressure, triglycerides, or glucose or reduced high-density lipoprotein cholesterol were recruited and randomly assigned to either a probiotic or placebo group (n = 26 each) for 90 days. During the study, 5 participants from the probiotic group withdrew, resulting in 21 participants for the probiotic group's endpoint analyses. Neither group received guidance regarding food intake. Participants underwent assessments of anthropometry, body composition, dietary intake, and a range of biochemical markers. No significant improvements were observed on cardiometabolic risk parameters following L lactis LMG 27352 supplementation. Dietary analysis further revealed a significant rise in carbohydrate intake in both groups. The findings of this study suggest limited clinical efficacy of L lactis LMG 27352 supplementation in metabolic disorders related to obesity under the conditions investigated. These results underscore the critical influence of dietary patterns, particularly sodium and carbohydrate intake, which may have modulated or counteracted any potential benefits of the probiotic strain.